Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16907820 | 0.89 | HTT (0.52) | HIF1ACSF1RALDH1A1HTTHPGD | |
| SCHEMBL1743265 | 0.89 | HSD17B1 (0.47) | HIF1ACSF1RALDH1A1HTTPKM | |
| SCHEMBL21198240 | 0.87 | HIF1A (0.42) | HIF1ACSF1RALDH1A1HTTPKM | |
| SCHEMBL18216864 | 0.86 | HIF1A (0.48) | HIF1ACSF1RALDH1A1HTTNPC1 | |
| SCHEMBL21202188 | 0.86 | HTT (0.59) | HIF1AALDH1A1HTTHPGDNPC1 | |
| SCHEMBL21198519 | 0.85 | GAA (0.41) | HIF1ACSF1RALDH1A1HTTPKM | |
| SCHEMBL14053701 | 0.84 | HIF1A (0.50) | HIF1ALPLLIPG | |
| SCHEMBL20132625 | 0.84 | GAA (0.48) | HIF1AALDH1A1HTTHPGDPKM | |
| SCHEMBL4523141 | 0.84 | KMT2A (0.47) | HIF1AALDH1A1HTTPKMGAA | |
| SCHEMBL2323198 | 0.84 | AAK1 (0.42) | HIF1ACSF1RALDH1A1HTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| EP-2675794-B1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2019-02-13 | — | — | EP | disclosed |
| US-10173991-B2 | Sulfone amide linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2878601-B1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | RIKEN (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-9604988-B2 | Agent for treating or inhibiting recurrence of acute myeloid leukemia | RIKEN (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160326125-A1 | SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2015-07-30 | — | — | US | disclosed |
| WO-2015105749-A1 | SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | HIF1A 1036/4885CSF1R 234/4885ALDH1A1 1374/4885 |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | HIF1A 3996/4885CSF1R 1036/4885ALDH1A1 2257/4885 |
| US-10173991-B2 | Sulfone amide linked benzothiazole inhibitors of endothelial lipase | LIPG, LIPE, LPL | HIF1A 3830/4885CSF1R 1141/4885ALDH1A1 426/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | HIF1A 132/4885CSF1R 1375/4885ALDH1A1 3327/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | HIF1A 3996/4885CSF1R 1036/4885ALDH1A1 2257/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | HIF1A 1170/4885CSF1R 1016/4885ALDH1A1 1059/4885 |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, BCOR, RUNX1 | HIF1A 342/4885CSF1R 117/4885ALDH1A1 439/4885 |
| US-20160326125-A1 | SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LIPE, LPL | HIF1A 3830/4885CSF1R 1141/4885ALDH1A1 426/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | HIF1A 2173/4885CSF1R 2959/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.